Rilpivirine

Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative, a class of molecules that resemble pyrimidine nucleotides found in DNA. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and an unlikely generation of resistance compared to other NNRTIs. Rilpivirine was developed by Tibotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with dolutegravir, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca.

SynZeal Research offers all Rilpivirine related impurities which certified COA with all characterization data like IR, Mass, HPLC purity, NMR & TGA report. We also provide CMR, DEPT and detailed structure characterization report as per requirements. Rilpivirine related products are being used by major pharmaceutical companies across the globe for their ANDA/DMF filing.

For more information on our products custom synthesis, contact SynZeal today.

standards@synzeal.com

www.synzeal.com